17347-61-4

Basic information

• Product Name: 2,2-Dimethylsuccinic anhydride
• Synonyms: 2,5-Furandione, dihydro-3,3-dimethyl-;3,3-Dimethyl-dihydro-furan-2,5-dione;dihydro-3,3-dimethylfuran-2,5-dione;2,2-DIMETHYLSUCCINIC ACID ANHYDRIDE;2,2-DIMETHYLSUCCINIC ANHYDRIDE;3,3-Dimethyl-3,4-dihydro-2,5-furandione;2,2-Dimethylsuccinic anhydride,98%;2-DiMethylsuccinic anhydride
• CAS NO: 17347-61-4
• Molecular Formula: C₆H₈O₃
• Molecular Weight: 128.13
• EINECS: 241-371-0
• Product Categories: Anhydride Monomers;Monomers;Polymer Science;Pyridines
• Mol File: 17347-61-4.mol
• Article Data: 12

Chemical Properties

• Melting Point: 29-31 °C(lit.)
• Boiling Point: 219-220 °C(lit.)
• Flash Point: 227 °F
• Appearance: White/Low Melting Solid
• Density: 1.135 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.114mmHg at 25°C
• Refractive Index: 1.4585 (estimate)
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 2,2-Dimethylsuccinic anhydride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-Dimethylsuccinic anhydride(17347-61-4)
• EPA Substance Registry System: 2,2-Dimethylsuccinic anhydride(17347-61-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• HazardClass: IRRITANT, MOISTURE SENSITIVE
• Hazardous Substances Data: 17347-61-4(Hazardous Substances Data)

Usage

Chemical Properties

white low melting solid

InChI:InChI=1/C6H8O3/c1-6(2)3-4(7)9-5(6)8/h3H2,1-2H3

Upstream product

• 13939-06-5 molybdenum hexacarbonyl 
• 75-98-9 Trimethylacetic acid 
• 151-50-8 potassium cyanide 
• 105-56-6 ethyl 2-cyanoacetate 
• 67-64-1 acetone 
• 597-43-3 2,2-dimethylsuccinic acid 
• 558-30-5 2-methyl-1,2-epoxypropane 
• 201230-82-2 carbon monoxide 
• 108483-64-3 α,α-Dimethyl-bernsteinsaeure-mono-(p-brom-phenyl)-ester 

Downstream Products

• 102563-49-5 1-Ethoxycarbonyl-4-methoxycarbonyl-4,4-dimethyl-2-oxobutylidenetriphenylphosphorane 
• 174022-42-5 bevirimat 
• 89531-67-9 2,2-Dimethyl-bersteinsaeure-4-amid 
• 741678-54-6 2,2-dimethyllycactonic acid 
• 26643-10-7 1-benzyloxy-3,3-dimethyl-pyrrolidine-2,5-dione 
• 322642-40-0 1-(4-methoxybenzyl)-3,3-dimethylpyrrolidine-2,5-dione 
• 42856-53-1 1-benzyl-3,3-dimethylpyrrolidine-2,5-dione 
• 791593-72-1 4-(4-bromophenyl)-2,2-dimethyl-4-oxo-butyric acid 
• 58457-63-9 4-(4-chlorophenyl)-2,2-dimethyl-4-oxobutanoic acid 
• 1085840-00-1 2,2-dimethyl-4-oxo-4-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenoxy}-piperidin-1-yl)-butyric acid 
• 1169569-99-6 3β-O-(3',3'-dimethylsuccinyl)-21-oxolup-18-en-28-oic acid N-benzylamide 
• 1169850-17-2 3β-O-(3',3'-dimethylsuccinyl)-17β-benzamido-21-oxolup-18-ene 

Relevant articles and documents

-

-

Synthesis of Cyclic Anhydrides via Ligand-Enabled C–H Carbonylation of Simple Aliphatic Acids

The development of C(sp3)–H functionalizations of free carboxylic acids has provided a wide range of versatile C?C and C?Y (Y=heteroatom) bond-forming reactions. Additionally, C–H functionalizations have lent themselves to the one-step preparation of a number of valuable synthetic motifs that are often difficult to prepare through conventional methods. Herein, we report a β- or γ-C(sp3)–H carbonylation of free carboxylic acids using Mo(CO)6 as a convenient solid CO source and enabled by a bidentate ligand, leading to convenient syntheses of cyclic anhydrides. Among these, the succinic anhydride products are versatile stepping stones for the mono-selective introduction of various functional groups at the β position of the parent acids by decarboxylative functionalizations, thus providing a divergent strategy to synthesize a myriad of carboxylic acids inaccessible by previous β-C–H activation reactions. The enantioselective carbonylation of free cyclopropanecarboxylic acids has also been achieved using a chiral bidentate thioether ligand.

PREPARATION OF PHARMACEUTICAL SALTS OF 3-O-(3',3'-DIMETHLSUCCINYL) BETULINIC ACID

This invention relates to a novel process for making 3-O-(3',3'- dimethylsuccinyl)betulinic acid ("DSB")- This invention also relates to methods of treating HIV and related diseases using pharmaceutical compositions comprising salt forms of DSB prepared according to the process of the present invention. The invention further relates to dosage forms of pharmaceutical compositions comprising salts of DSB made using the process of this invention.